ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

“Imaginary Treatments,” “Wonderful Cures”

June 6, 1997

NCI To Lose 19% of Workforce Over Six Years, Broder Says

November 4, 1994

USDA Expands Role In 5 A Day Partnership

April 26, 2002

Million Dollar Awards Pace Contracts Rush

July 4, 1975

Men Over Age 75 Shouldn’t Be Screened For Prostate Cancer, Task Force Says

August 29, 2008

With Flashing Lights, Heckling, and Folk Song, Avastin Sets New Tone for FDA Debates

July 1, 2011